Larimar Therapeutics Inc (NASDAQ:LRMR) shares, rose in value on Thursday, March 27, with the stock price up by 6.67% to the previous day’s close as strong demand from buyers drove the stock to $2.40.
Actively observing the price movement in the last trading, the stock closed the session at $2.25, falling within a range of $2.21 and $2.44. The value of beta (5-year monthly) was 0.772. Referring to stock’s 52-week performance, its high was $11.20, and the low was $2.19. On the whole, LRMR has fluctuated by -18.09% over the past month.
With the market capitalization of Larimar Therapeutics Inc currently standing at about $153.67 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-23.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LRMR’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of LRMR currently trading nearly -9.33% and -22.49% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 38.58, while the 7-day volatility ratio is showing 8.74% which for the 30-day chart, stands at 8.58%. Furthermore, Larimar Therapeutics Inc (LRMR)’s beta value is 0.87, and its average true range (ATR) is 0.22.
A comparison of Larimar Therapeutics Inc (LRMR) with its peers suggests the former has fared considerably weaker in the market. LRMR showed an intraday change of 6.67% in last session, and over the past year, it shrunk by -68.34%%.
Data on historical trading for Larimar Therapeutics Inc (NASDAQ:LRMR) indicates that the trading volumes over the past 10 days have averaged 1.16 and over the past 3 months, they’ve averaged 647.16K. According to company’s latest data on outstanding shares, there are 63.82 million shares outstanding.
Nearly 42.86% of Larimar Therapeutics Inc’s shares belong to company insiders and institutional investors own 59.05% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.08 million shares as on 2025-03-14, resulting in a short ratio of 9.37. According to the data, the short interest in Larimar Therapeutics Inc (LRMR) stood at 1218.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 5.38 million. The stock has fallen by -37.98% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LRMR stock heading into the next quarter.
